ISAL 2023 | ISAL session highlights: gemtuzumab & small molecule inhibitors with chemotherapy in AML and APL
Alan Burnett
• 21 Mar 2023
Alan Burnett, MD, University of Glasgow, Glasgow, UK, shares some of the topics that were discussed at a session on treatments for acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) that took place at this year’s ISAL meeting, commenting on trial activity, the use of gemtuzumab ozogamicin, and the increasing use of small molecules inhibitors with chemotherapy, particularly in older patients. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
